Does SECUKINUMAB Cause Tonsillar hypertrophy? 42 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Tonsillar hypertrophy have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.0% of all adverse event reports for SECUKINUMAB.
42
Reports of Tonsillar hypertrophy with SECUKINUMAB
0.0%
of all SECUKINUMAB reports
0
Deaths
11
Hospitalizations
How Dangerous Is Tonsillar hypertrophy From SECUKINUMAB?
Of the 42 reports, 11 (26.2%) required hospitalization, and 2 (4.8%) were considered life-threatening.
Is Tonsillar hypertrophy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 42 reports have been filed with the FAERS database.
What Other Side Effects Does SECUKINUMAB Cause?
Drug ineffective (27,434)
Psoriasis (21,976)
Pain (15,244)
Arthralgia (13,769)
Fatigue (9,406)
Psoriatic arthropathy (8,900)
Pruritus (8,755)
Malaise (8,570)
Rash (8,023)
Condition aggravated (7,536)
What Other Drugs Cause Tonsillar hypertrophy?
ADALIMUMAB (151)
ONDANSETRON (51)
SOMATROPIN (43)
DUPILUMAB (39)
METHOTREXATE (39)
INFLIXIMAB (31)
TACROLIMUS (26)
INFLIXIMAB-DYYB (25)
ETANERCEPT (24)
LAMOTRIGINE (24)
Which SECUKINUMAB Alternatives Have Lower Tonsillar hypertrophy Risk?
SECUKINUMAB vs SELADELPAR LYSINE
SECUKINUMAB vs SELEGILINE
SECUKINUMAB vs SELENIUM
SECUKINUMAB vs SELENIUM SULFIDE
SECUKINUMAB vs SELEXIPAG